Site-specific effects of cerivastatin on bone in male Sprague-Dawley rats

Bone

Volumn 34, Issue 3, 2004, Pages 432-442

  Banu, Jameela ^a   Kalu, Dike N ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Bone loss; Cerivastatin; SD rats

Indexed keywords

CERIVASTATIN; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE; BONE AGE; BONE DENSITY; BONE MASS; BONE MINERAL; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; DENSITOMETRY; DIAPHYSIS; DOSE RESPONSE; DRUG EFFECT; FEMUR; FEMUR NECK; FIBULA; GROWTH PLATE; MALE; METAPHYSIS; NONHUMAN; OSTEOLYSIS; RAT; RAT STRAIN; TIBIA;

ANIMALS; BONE AND BONES; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMUR; MALE; OSTEOPOROSIS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TIBIA;

EID: 1542376114     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.10.008     Document Type: Article

References (50)

1. Banu M.J., Orhii P.B., Wang L., Kalu D.N. Separate and combined effects of growth hormone and parathyroid hormone on cortical bone osteopenia in ovariectomized aged rats. Aging Clin. Exp. Res. 13:2001;282-292.
2. Banu M.J., Orhii P.B., Wang L., Kalu D.N. Separate and combined effects of growth hormone and parathyroid hormone on cortical bone osteopenia in ovariectomized aged rats. Aging Clin. Exp. Res. 13:2001;82-292.
3. Banu J., Kalu D.N. Effects of cerivastatin and parathyroid hormone on the lumbar vertebra of aging male Sprague Dawley rats. Bone. 31:2002;173-179.
4. Bischoff H., Angerbauer R., Bender J., Bischoff E., Faggiotto A., Petzinna D.et al. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Artherosclerosis. 135:1999;119-130.
5. Burr D.B. Muscle strength, bone mass, and age related bone loss. J. Bone Miner. Res. 12:1997;1547-1551.
6. Cauley J.A., Jackson R., Petinger M., LaCroix A., Bauer D., Chen Z.et al. Statin use and bone mineral density (BMD) in older women: the Women's Health Initiative Observational Study (WHI-OS). J. Bone Miner. Res. 15:2000;S155. [Suppl.].
7. Ejersted C., Andreassen T.T., Oxlund H., Jorgensen P.H., Bak B., Haggblad J.et al. Human parathyroid hormone (1-34) and (1-84) increases the mechanical strength and thickness of cortical bone in rats. J. Bone Miner. Res. 8:1993;1097-1101.
8. Ejersted C.C., Andreassen T.T., Nilsson M.H.L., Oxlund H. Human parathyroid hormone (1-34) increase bone formation and strength of cortical bone in aged rats. Eur. J. Endocrinol. 130:1994;201-207.
9. Farmer J.A. Learning from the cerivastatin experience. Lancet. 358:2001;1383-1384.
10. FDA talk paper. FDA approves teriparatide to treat osteoporosis. T02-49. Nov, 26, 2002.
11. Ferretti J.L. Peripheral quantitative computed topography (pQCT) for evaluating structural and mechanical properties of small bone. An Y.H., Draughan R.A. Practical guide for mechanical testing of bone. 1999;1-25 CRC Press, Boca Raton (FL).
12. Frost H.M. Osteoporosis: their nature, and therapeutic drugs (insights from a new paradigm). Whitfield J.F., Morely P. Anabolic treatment for osteoporosis. 1997;1-29 CRC Press, Boca Raton.
13. Frost H.M. On our age-related bone loss: insights from a new paradigm. J. Bone Miner. Res. 12:1997;1539-1546.
14. Garrett I.R., Escobedo A., Esparza J., Mundy G.R. Cerivastatin increases BMP-2 expression in vivo and bone formation in concentrations two orders of magnitude lower than other statins. J. Bone Miner. Res. 14(Suppl. 1):1999;S180.
15. Gasser J.A. Quantitative assessment of bone mass and geometry by pQCT in rats in vivo and site-specificity of changes at different skeletal sites. J. Jpn. Soc. Bone Morphom. 7:1997;107-114.
16. Gasser J.A. Fluvastatin and cerivastatin are not anabolic for bone after local or systemic administration of non-toxic doses in mice and rats. J. Bone Miner. Res. 16:2001;S295. [Suppl.].
17. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am. J. Med. 103:1997;S20-S26.
18. Kalu D.N., Echon R., Hollis B.W. Modulation of ovariectomy related bone loss by parathyroid hormone in rats. Mech. Ageing Dev. 56:1990;49-62.
19. LaCroix A.Z., Cauley J.A., Jackson R., McGowan J., Pettinger M., Hisa J.et al. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study. J. Bone Miner. Res. 15:2000;S155. [Suppl.].
20. Li X.J., Jee W.S.S., Chow S.-Y., Woodbury D.M. Adaptation of cancellous bone to aging and immobilization in the rat: a single photon absorptiometry and histomorphometry study. Anat. Rec. 227:1990;12-24.
21. Li M., Mosekilde L., Sogaard C.H., Thomsen J.S., Wronski T.J. Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone. 16:1995;629-635.
22. Lindsay R., Cosman F., Herrington B.S., Himmelstein S. Bone mass and body composition in normal women. J. Bone Miner. Res. 7:1992;55-63.
23. Looker A.C., Orwoll E.S., Johnston C.C. Jr., Lindsay R.L., Wahner H.W., Dunn W.L.et al. Prevalence of low femoral bone density in older US adults from NHANES III. J. Bone Miner. Res. 12:1997;1761-1768.
24. Melton L.J. III, Atkinson E.J., O'Connor M.K., O'Fallen W.M., Riggs B.L. Bone density and fracture risk in men. J. Bone Miner. Res. 13:1998;1915-1923.
25. Melton L.J. III The prevalence of osteoporosis: gender and racial composition. Calcif Tissue Int. 69:2001;179-181.
26. Martin R.B., Burr D.B. Structure, function and adaptation of compact bone. 1989;230-233 Raven Press, New York.
27. Mosekilde I., Sogaard C.H.M., Danielssen C.C., Torring O., Nilsson M.H.L. The anabolic effect of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quantity of bone assessed by mechanical testing: a comparison study between hPTH (1-34) and hPTH (1-84). Endocrinology. 129:1991;421-428.
28. Mosekilde L., Sogaard C.H., McOskar J.E., Wronski T.J. Parathyroid hormone has more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonates)-assessed in sexually mature ovariectomized rats. Bone. 15:1994;401-405.
29. Mosekildem Li, Danielsen C.C., Gasser J.A. The effect of vertebral bone mass and strength of long term treatment with anti-resorptive agents (estrogen and calcitonin) human parathyroid hormone (1-38) and combination therapy, assessed in aged ovariectomized rats. Endocrinology. 134:1994;2126-2134.
30. Mosekilde Li, Reeve J. Treatment with PTH peptides. Marcus R., Feldman D., Kelsey J. Osteoporosis. 1996;1293-1311 Academic Press, San Diego (CA).
31. Mosekilde Li Mechanism and models in anabolic treatments for osteoporosis. Whitefield J.F., Morley P. Osteoporosis. 1998;31-58 CRC Press, Bacon Raton (FL).
32. Mitlak B.H. Parathyroid hormone as a therapeutic agent. Curr. Opin. Pharmacol. 2:2002;694-699.
33. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G.et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949.
34. Mundy G.R. Statins and their potential for osteoporosis. IBMS BoneKey. 2001;. http://www.BoneKEy-IBMS.org.
35. Orwall E.S., Scheele W.H., Paul S., Adami S., Syversen V., Diez-Perez A.et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18:2003;9-17.
36. Oxlund H., Ejersted C., Andreassen T.T., Torring O., Nilsson M.H.L. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation from periosteum and endosteum. Calcif Tissue Int. 53:1993;394-399.
37. Oxlund H., Dalstra M., Andreassen T.T. Statin given perorally to adult rat increases cancellous bone mass and compressive strength. Calcify Tissue Int. 69:2001;299-304.
38. Rowe J.W., Kahn R.L. Human aging: usual and successful. Science. 237:1989;143-149.
39. Salamone L.M., Glynn U., Black D., Epstein R.S., Palermo L., Meilahn E. et al. Body composition and bone mineral density in premenopausal and early perimenopausal women. J. Bone Miner. Res. 10:1995;1762-1768.
40. Schiessel H., Willnecker J. Muscle cross-sectional area and bone cross-sectional area in the human lower leg measured with peripheral computed tomography. Lyritis G.P. Musculoskeletal interactions. vol. 2:1999;47-52 Hylonome, Greece.
41. Thomsen J.S., Mosekilde Li, Gasser J.A. Long term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog ADZ PTS 893 and bone maintenance in retired breeder rats. Bone. 25:1999;561-569.
42. Tuukkanen J., Wallmark B., Jalovaara P., Takala T., Sjogren S., Vaananen K. Changes induced in growing rat bone by immobilization and remobilization. Bone. 12:1991;113-118.
43. Van staa T.P., Wegman S.L.J., de Vries F., Leufkens H.G.M., Cooper C. Use of statins and risk of fractures. JAMA. 11(285):2001;1850-1855.
44. Wang L., Orhii P.B., Banu J., Kalu D.N. Effects of separate and combined therapy with growth hormone and parathyroid hormone on lumbar vertebral bone in aged ovariectomized osteopenic rats. Bone. 28:2001;202-207.
45. Wang L., Orhii P.B., Banu J., Kalu D.N. Effects of separate and combined therapy with growth hormone and parathyroid hormone on the femoral neck in aged ovariectomized osteopenic rats. Mech. Ageing Dev. 122:2001;89-104.
46. Wang L., Banu J., McMahan A.C., Kalu D.N. Male rodent model of age-related bone loss in men. Bone. 29:2001;141-148.
47. Weber W. Drug firm withdraws statin from the market. Lancet. 358:2001;568.
48. Weinreb M., Rodan G.A., Thompson D.D. Osteopenia in immobilized rat hind limb is associated with increased bone resorption and decreases bone formation. Bone. 10:1989;187-194.
49. Welten D.K., Kemper H.C.G., Post G.B., van Mechelen W.Q., Tirsk J., Lips P.et al. Weight bearing activity during youth is a more important factor for peak bone mass than calcium intake. J. Bone Miner. Res. 9:1994;1089-1096.
50. Woo S.L.Y., Knei S.C., Amiel D., Gomez M.A., Hayes W.C., White F.C.et al. The effect of prolonged physical training on the properties of long bone. A study of Wolffe's law. J. Bone Joint Surg. 63A:1981;780-787.